Moderna and Immatics aim to see if the combination of their respective technologies can lead to better cancer treatments spanning multiple therapeutic modalities. Milestone payments to immunotherapy developer Immatics could top $1.7 billion.
Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Moderna and Merck have been partners in the development of messenger RNA cancer vaccines since 2016. Merck is deepening the alliance by exercising an option that enables it to share equally in further work on a partnered cancer vaccine for melanoma.
Notwithstanding significant progress made in the past decade in the fight against cancer, this disease remains the world's second-largest cause of death, behind cardiovascular disease. Now, mRNA cancer vaccines could offer some hope.
Vaccines developed by Aivita Biomedical use a patient's own blood to attack cancer and Covid-19. But the company also offers a consumer skin-care product that it plans to begin selling more widely.
Ugur Sahin presented a sweeping vision of the company's goal to become a next-generation immunotherapy company leveraging the messenger RNA platform technology that has won it acclaim and financial returns during the Covid-19 pandemic.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The deal includes an upfront payment and up to 100 million euros in milestones, equaling $364.5 million. Amal's lead candidate is a vaccine for colorectal cancer expected to enter the clinic later this month.
PsiOxus Therapeutics has signed a second agreement with Bristol-Myers Squibb (BMS), this time for worldwide rights to its 'armed' oncolytic virus NG-348, currently in the preclinical research phase.
BeneVir's cancer vaccines are engineered to incite an immune response, as well as hide from the immune system - so as to have a prolonged anti-cancer effect.
Bay Area cancer vaccine maker Bullet Biotechnology is developing a therapy for B cell lymphomas, hacking a patient’s own immune system to treat these cancers. It takes the typical vaccine approach – targeting a marker exclusive to B cells that elicits a cellular immune response – from both T and B cells. Bullet uses directed conjugation to attach a […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.